Mycosis Fungoides / Sézary Syndrome · line 2 · Bexarotene low-dose maintenance for CTCL responders (75-150 mg/m² PO daily)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-BEXAROTENE-MAINTENANCE-CTCL |
| ID | IND-MF-MAINTENANCE-RETINOID |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-MF-SEZARY |
| Sources | SRC-ESMO-CTCL-2024 SRC-NCCN-BCELL-2025 |
Notes
STUB. Maintenance applicable across induction backbones (post-bexarotene full-dose, post-mogamulizumab, post-BV). Major UA access barrier — supply continuity is critical operational concern.
Used By
Algorithms
ALGO-MF-SEZARY-2L- ALGO-MF-SEZARY-2L
Indication
IND-MF-ADVANCED-2L-BEXAROTENE- IND-MF-ADVANCED-2L-BEXAROTENE